cancer treatment

HER3-DXd Withdraws Market Application: What Lies Ahead for ADC Innovative Drugs?

by
HER3-DXd Withdraws Market Application: What Lies Ahead for ADC Innovative Drugs?

This article has a total of2229words, reading time:3-4 minutes ｜Author: MaxTom On May 29, 2025, Merck and Daiichi Sankyo jointly announced thevoluntary withdrawal of the market application for the HER3-targeted antibody-drug conjugate (ADC), Patritumab deruxtecan (HER3-DXd), which was originally seeking accelerated approval for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who … Read more

ADC Drugs: The ‘Magic Bullets’ for Cancer Treatment

by
ADC Drugs: The 'Magic Bullets' for Cancer Treatment

1. Overview of ADC Drugs Antibody-drug conjugates (ADCs) are referred to as the ‘magic bullets’ for cancer treatment. They are a new type of biotherapeutic drug that combines monoclonal antibodies with cytotoxic drugs through a chemical linker. The core concept is to combine the specific targeting ability of antibodies with the powerful killing effect of … Read more

ADC and Click Chemistry

by
ADC and Click Chemistry

–01– Introduction The announcement of the 2022 Nobel Prize in Chemistry brought the cutting-edge technology of “Click Chemistry” into the public eye. The groundbreaking work of three scientists has not only revolutionized the field of organic synthesis but also opened new pathways for cancer treatment—specifically, the development of Antibody-Drug Conjugates (ADC) is advancing towards a … Read more

2025 ASCO Review: ADC Continues to Lead Cancer Treatment, Innovative Target Efficacy Begins to Show, Domestic Technology Platforms Achieve Multidimensional Breakthroughs

by
2025 ASCO Review: ADC Continues to Lead Cancer Treatment, Innovative Target Efficacy Begins to Show, Domestic Technology Platforms Achieve Multidimensional Breakthroughs

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting grandly opened in Chicago on May 31, lasting for 4 days, with the theme “Driving Knowledge to Action: Building a Better Future,” focusing on the latest research progress and innovative translational achievements in the global cancer treatment field. ADC drugs remain a hot area of … Read more

These Two Companies’ ADC Products Ride the Wave of Global PD-1 Sales Champions, Why Worry About Future Sales?

by
These Two Companies' ADC Products Ride the Wave of Global PD-1 Sales Champions, Why Worry About Future Sales?

We previously mentioned that the current standard treatment for cancer is gradually shifting from PD-1 + chemotherapy to PD-1 + ADC drugs. According to relevant data, the global ADC drug market size has grown from $7.9 billion in 2022 to approximately $20 billion in 2024, showing strong growth momentum. Among them, DS8201 (HER2 ADC), jointly … Read more

Understanding Peptide-Drug Conjugates (PDC) in the Wave of ADCs

by
Understanding Peptide-Drug Conjugates (PDC) in the Wave of ADCs

In cancer treatment, there are three targeted approaches to enhance the specificity and anti-tumor activity of therapies. Targeted formulations can be designed to inhibit proteins expressed by tumor cells, such as receptors or enzymes; another approach involves binding effector molecules (e.g., ADCs, bispecific antibodies, or CAR-T) to molecules overexpressed on the surface of tumor cells, … Read more

A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy

by
A Multi-Threshold Micelle Improves Tumor Accumulation and STING Immunotherapy

In the field of cancer immunotherapy, activating STING (Stimulator of Interferon Genes) is a key strategy to stimulate anti-cancer immune responses. STING, as an important innate immune protein, enhances anti-cancer immunity through type I interferon signaling. However, traditional STING agonists face numerous challenges during intravenous administration, such as short blood circulation half-life and insufficient tumor … Read more

Advancements in Magnetic Microrobots for Cancer Treatment: Performing Specific Tasks Independently

by
Advancements in Magnetic Microrobots for Cancer Treatment: Performing Specific Tasks Independently

The limbs of the LEGO figure in the image can move independently because the magnetic screws connecting its limbs are in a specially designed layered magnetic field. On February 23, Beijing time, foreign media reported that a recent study suggests that magnetically controlled microrobots may one day help us combat cancer. Over the past decade, … Read more

The Predicament of Established ADC Biotech

by
The Predicament of Established ADC Biotech

Not all long-established ADC Biotechs can achieve a successful exit like Seagen (Seattle Genetics). Today, Mersana Therapeutics, a 23-year-old veteran biotech, has reached its most desperate moment. With a cumulative deficit of $900 million and only $134.6 million left in cash, its two core pipeline products are still in Phase I clinical trials. To sustain … Read more

Rapid Advances in ADC: A Cold Reflection Amidst Global Competition

by
Rapid Advances in ADC: A Cold Reflection Amidst Global Competition

01 Domestic B7H3 ADC: From Clinical Data to Market Ambitions In 2024, the global ADC landscape is set to reach a turning point amidst the celebration of DS-8201 breaking the $10 billion expectation, with the B7H3 target emerging as a dark horse and becoming the next storm center. Taking domestic products as an example, although … Read more